Faculty Profile


  • Dr. Fadhil is a board-certified vascular and interventional neurologist at the University of Texas Medical Branch. He completed his neurology residency and vascular neurology fellowship at University Hospitals/Case Western Reserve University, followed by an interventional neurology fellowship at the University of Pittsburgh Medical Center. Before joining UTMB, he served on the faculty at UPMC, where he was actively involved in stroke care and resident education.

    At UTMB, Dr. Fadhil serves as Director of the Vascular Neurology Fellowship and is dedicated to advancing training in comprehensive stroke management and endovascular therapy. His clinical expertise includes acute stroke intervention, carotid and intracranial stenting, and the management of complex aneurysms and cerebrovascular disease. His research focuses on cerebrovascular imaging, carotid revascularization outcomes, and endovascular device performance, with multiple peer-reviewed publications and ongoing collaborations aimed at optimizing stroke systems of care and advancing neurointerventional techniques.

  • Medical/Professional School:

    Al-Nahrain University College of Medicine, Baghdad, Iraq 2007

    Internships:

    Cleveland Clinic Foundation/Fairview Hospital Residency Program, Cleveland, OH, 2018

    Residencies:

    Neurology, University Hospitals/Case Western Reserve University, Cleveland, OH 2021

    Fellowships:

    Fellowship – Interventional Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA 2025

    Vascular Neurology, University Hospitals/Case Western Reserve University, Cleveland, OH 2022

    Pre-residency Fellowship, Neurosurgery, Boston Medical Center, Boston, MA 2017


    Certifications:

    American Board of Psychiatry and Neurology – Neurology

    American Board of Psychiatry and Neurology – Vascular Neurology

    • Q.F.B. Chemistry and Pharmacobiology, Faculty of Chemical Sciences. Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

    • Ph.D. Neurobiology, Faculty of Biological Sciences, Universidad Nacional Autónoma de Mexico, CDMX, Mexico

    • Postdoctoral Fellow, ORISE. Division of Neurotoxicology, Laboratory of Neurochemistry, National Center for Toxicological Research, Food and Drug Administration, USA
    • Sex differences in neurodegenerative diseases, mainly in AD

    • Role of the blood-brain barrier in AD

    • Neurotoxicity in Neurodegenerative Diseases

    • Neuroinflammation in Neurodegenerative Diseases
    • Perez-Severiano F, Salvatierra-Sanchez R, Rodriguez-Perez M, Cuevas-Martinez EY, Guevara J, Limon D, Maldonado PD, Medina-Campos ON, Pedraza-Chaverri J, Santamaria A (2004) S-Allylcysteine prevents amyloid-beta peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol 489, 197-202.

    • Cuevas E, Limon D, Perez-Severiano F, Diaz A, Ortega L, Zenteno E, Guevara J (2009) Antioxidant effects of epicatechin on the hippocampal toxicity caused by amyloid-beta 25-35 in rats. Eur J Pharmacol 616, 122-127.

    • Cuevas E, Lantz SM, Tobon-Velasco JC, Newport GD, Wu Q, Virmani A, Ali SF, Santamaria A (2011) On the in vivo early toxic properties of A-beta 25-35 peptide in the rat hippocampus: involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression. Neurotoxicol Teratol 33, 288-296.

    • Cuevas E, Rosas-Hernandez H, Burks SM, Ramirez-Lee MA, Guzman A, Imam SZ, Ali SF, Sarkar S (2019) Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro. Metab Brain Dis 34, 1365-1374.

    • Gu Q, Cuevas E, Raymick J, Kanungo J, Sarkar S (2020) Downregulation of 14-3-3 Proteins in Alzheimer's Disease. Mol Neurobiol 57, 32-40.

    • Sarkar S, Raymick J, Cuevas E, Rosas-Hernandez H, Hanig J (2020) Modification of methods to use Congo-red stain to simultaneously visualize amyloid plaques and tangles in human and rodent brain tissue sections. Metab Brain Dis 35, 1371-1383.

    • Rosas-Hernandez H, Cuevas E, Raymick JB, Robinson BL, Sarkar S (2020) Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease. Neuroscience 440, 48-55.

    • Apatiga-Perez R, Soto-Rojas LO, Campa-Cordoba BB, Luna-Viramontes NI, Cuevas E, Villanueva-Fierro I, Ontiveros-Torres MA, Bravo-Munoz M, Flores-Rodriguez P, Garces-Ramirez L, de la Cruz F, Montiel-Sosa JF, Pacheco-Herrero M, Luna-Munoz J (2021) Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease. Metab Brain Dis.
  • 2020NCTR Special act award
    2019NCTR Special act award
    2018Member of the Mexican SNI, Level 1, by CONACyT, Mexico
    2017 - 2018President of the Arkansas Chapter of the Society for Neuroscience
    2014Travel award to Workshop Collaborative zebrafish model
    2014Quality of Life Award, NCTR
    2008First Place in "Science Fair", as a PI, UNAM
  • 2020 - PresentInternational Society to Advance Alzheimer's Research and Treatment
    2010 - PresentArkansas Chapter of the Society for Neuroscience
    2002 - PresentSociety for Neuroscience